Enterprise workshop trial design R4P – The Global HIV Vaccine Enterprise

Design Approaches for Current and Future HIV Prevention Efficacy Trials

Scientific workshop – Cape Town, South Africa, 21-22 January 2021

SAVE THE DATE

21 – 22 January 2021

SCIENTIFIC WORKSHOP

Cape Town, South Africa

“Design Approaches for Current and Future HIV Prevention Efficacy Trials”

Hosted by The Global HIV Vaccine Enterprise in partnership
with the HIV Vaccine Trials Network

HIV prevention is evolving rapidly with the roll out of new tools such as pre-exposure prophylaxis (PrEP) and treatment as prevention making a significant contribution towards controlling the epidemic. As a result, the design and conduct of the next generation of prevention trials is impacted and will be further affected by the outcomes of ongoing HIV prevention efficacy trials – including oral and injectable antiretrovirals, passively infused monoclonal antibodies, and HIV vaccines.

This scientific and technical workshop aims to continue from the first HIV Prevention Efficacy Trial Designs of the Future symposium, held in November 2018 in Seattle by the Fred Hutch and the NIAID, which led to a series of articles published in Statistical Communications in Infectious Diseases and a viewpoint in The Lancet HIV.

In this follow-up workshop, participants will reflect on more recent advances and challenges within the HIV prevention field and on the rationale and lessons learned for current HIV prevention designs. They will examine novel scientific approaches for establishing efficacy of new biologics in a future where all trial participants have access to effective prevention.

The two-day event will feature a series of talks given by biostatisticians and clinical trial experts, and will include panel discussions with clinicians, ethicists, regulators, community members and sponsors.

A series of articles, based on the talks given at the symposium, will be published in a selected high-impact journal.

Please share among your network.

More details of the day’s events and an agenda will be sent out closer to the date.

Organizing committee

Holly Prudden, International AIDS Society, Geneva, Switzerland.
Holly Janes, Fred Hutchinson Cancer Research Center, Seattle, USA.
Deborah Donnell, Fred Hutchinson Cancer Research Center, Seattle, USA.
Roger Tatoud, International AIDS Society, Geneva, Switzerland.
Linda-Gail Bekker. Desmond Tutu HIV Centre, University of Cape Town (UCT), South Africa.

For immediate queries, please contact holly.prudden@iasociety.org.

The organization of this workshop is supported by a grant from the Bill and Melinda Gates Foundation and the US National Institutes of Health (NIH).

Trial Design Approaches 2020 - Workshop

Cape Town 15-16 October 2020

Name*
First Last
Location*
Country
Occupation*
Email*
Enter Email Confirm Email
Consent to Privacy Policy*
When you visit our website some personal information may be collected by the IAS. We will only use such information for the purposes of (i) administering certain programmes as identified to you at the time of collection, (ii) a form where the information is no longer identifiable with you, for statistical and marketing analyses and (iii) registration to on of the conference for which IAS is an organizer or co-organizer.

The IAS is committed to protecting your privacy and takes its responsibilities regarding the security of your information very seriously. The IAS requires certain information to allow your registration. The IAS collects the details provided by you, together with information it learns about you form your use of IAS service and your visits to IAS websites and other sites accessible from them. The IAS also collects information about the transactions you undertake including details of payment cards used. The IAS will also use your contact details to communicate with you.

The information that you provide to the IAS will be held in the IAS systems, which are located on our premises or those of an appointed third party. The IAS may also allow access to your information by other third parties who act for the IAS, namely for the purposes of registration, accommodation, travel and for abstract submission. Should the IAS consider possible to disclose some of your information to third parties beyond the scope of purposes stated above, you will be notified before giving such information to the IAS.

In using an IAS website, you consent to the collection and use of this information in the ways described above. Should you have any question in relations to this privacy policy, please contact us at info@iasociety.org.

If the IAS decides to change its Privacy Policy, those changes will be mentioned on this page so that you are always aware of what information is collected, how the IAS uses it and in what circumstances such information may be disclosed.
I agree to the privacy policy.
Comments
This field is for validation purposes and should be left unchanged.

Design Approaches for Current and Future HIV Prevention Efficacy Trials

Trial Design Approaches 2020 - Workshop

About

Global HIV Vaccine Enterprise

Contact Us